Since this unprecedented efficacy is recapitulated in reconstituted CF patient tissue, type IV correctors whose drug-like properties will be described in due course could represent a promising new treatment modality for CF patients with CFTR folding mutations. The gene discussed is CFTR; the disease is cystic fibrosis.